

REPROS THERAPEUTICS INC.  
Form 8-K  
August 05, 2013

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 8-K**

**Current Report Filed Pursuant to Section 13 or 15(d) of**

**The Securities Exchange Act of 1934**

**Date of Report**

**(Date of earliest event reported): August 5, 2013**

**Repros Therapeutics Inc.**

**(Exact name of registrant as specified in its charter)**

**Delaware**  
**(State or other jurisdiction of incorporation or**  
**organization)**

**001-15281**  
**(Commission File**  
**Number)**

**76-0233274**  
**(I.R.S. Employer Identification**  
**No.)**

**2408 Timberloch Place, Suite B-7**

**The Woodlands, Texas 77380**

**(Address of principal**

**executive offices**

**and zip code)**

**(281) 719-3400**

**(Registrant's telephone number, including area code)**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2 below):

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Item 8.01 Other Events.**

On August 5, 2013 the Registrant issued a press release, a copy of which is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

**Item 9.01 Financial Statements and Exhibits.**

Exhibit 99.1. Press release dated August 5, 2013

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934 the Company has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**Repros Therapeutics Inc.**

Date: August 5, 2013

By: /s/ Kathi Anderson  
Kathi Anderson  
Chief Financial Officer

**EXHIBIT INDEX**

Exhibit

Number Description

99.1 Press release dated August 5, 2013